PTEN loss is more often found in BRAF-mutant than in NRAS-mutant melanoma [67], a finding compatible with PI3K/AKT pathway activation by NRAS but not BRAF mutations, which need an additional hit. This evidence concerns the gene NRAS and melanoma.